The global fibromyalgia treatment market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of fibromyalgia and rising awareness about the disease. The major players in this market are Eli Lilly and Company, Pfizer Inc, Johnson & Johnson, AbbVie Inc, AstraZeneca plc, Merck & Co., Inc, Novartis AG, GlaxoSmithKline plc, Sanofi S.A., Bristol-Myers Squibb Company and Allergan PLC.
Some Of The Growth Factors Of This Market:
- The number of people with fibromyalgia is increasing, which will lead to an increase in the demand for treatment.
- There are many new treatments being developed for fibromyalgia, which will lead to an increase in the supply of treatment.
- The cost of treatment is decreasing, which will lead to an increase in the demand for treatment.
- There are more doctors who specialize in treating fibromyalgia, which will lead to an increase in the supply of treatment and a decrease in the cost of treatment.
- More research is being done on how best to treat fibromyalgia, which will lead to more effective treatments.
Industry Growth Insights published a new data on “Fibromyalgia Treatment Market”. The research report is titled “Fibromyalgia Treatment Market research by Types (Antidepressants, Anticonvulsants, Muscle Relaxants, Narcotic Analgesics, Non-narcotic Analgesics), By Applications (Hospitals Pharmacies, Clinic Pharmacy, Retail Drug Stores, Online Pharmacies), By Players/Companies Eli Lilly and Company, Pfizer, Novartis AG, Allergan, Aptinyx, Prismic Pharmaceuticals, Innovative Med Concepts, Intec Pharma Ltd., Astellas Pharma, Savella, Sun Pharmaceutical Industries, Mylan NV, Teva Pharmaceutical Industries, Daiichi Sankyo, Forest Pharmaceuticals, Meiji Seika Pharma, Tonix Pharmaceuticals, Theravance Biopharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Fibromyalgia Treatment Market Research Report
By Type
Antidepressants, Anticonvulsants, Muscle Relaxants, Narcotic Analgesics, Non-narcotic Analgesics
By Application
Hospitals Pharmacies, Clinic Pharmacy, Retail Drug Stores, Online Pharmacies
By Companies
Eli Lilly and Company, Pfizer, Novartis AG, Allergan, Aptinyx, Prismic Pharmaceuticals, Innovative Med Concepts, Intec Pharma Ltd., Astellas Pharma, Savella, Sun Pharmaceutical Industries, Mylan NV, Teva Pharmaceutical Industries, Daiichi Sankyo, Forest Pharmaceuticals, Meiji Seika Pharma, Tonix Pharmaceuticals, Theravance Biopharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Fibromyalgia Treatment Market Report Segments:
The global Fibromyalgia Treatment market is segmented on the basis of:
Types
Antidepressants, Anticonvulsants, Muscle Relaxants, Narcotic Analgesics, Non-narcotic Analgesics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals Pharmacies, Clinic Pharmacy, Retail Drug Stores, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly and Company
- Pfizer
- Novartis AG
- Allergan
- Aptinyx
- Prismic Pharmaceuticals
- Innovative Med Concepts
- Intec Pharma Ltd.
- Astellas Pharma
- Savella
- Sun Pharmaceutical Industries
- Mylan NV
- Teva Pharmaceutical Industries
- Daiichi Sankyo
- Forest Pharmaceuticals
- Meiji Seika Pharma
- Tonix Pharmaceuticals
- Theravance Biopharma
Highlights of The Fibromyalgia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antidepressants
- Anticonvulsants
- Muscle Relaxants
- Narcotic Analgesics
- Non-narcotic Analgesics
- By Application:
- Hospitals Pharmacies
- Clinic Pharmacy
- Retail Drug Stores
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fibromyalgia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for fibromyalgia will vary depending on the individual's symptoms and medical history. However, some common treatments for fibromyalgia include:nnu2013 Physical therapy: This may help improve range of motion and flexibility in the body, which can help reduce pain.nnu2013 Medications: Some people with fibromyalgia may benefit from medications such as antidepressants or painkillers. It is important to discuss any potential medications with a doctor before starting them, as they can have side effects that could worsen your condition.
Some of the major players in the fibromyalgia treatment market are Eli Lilly and Company, Pfizer, Novartis AG, Allergan, Aptinyx, Prismic Pharmaceuticals, Innovative Med Concepts, Intec Pharma Ltd., Astellas Pharma, Savella, Sun Pharmaceutical Industries, Mylan NV, Teva Pharmaceutical Industries, Daiichi Sankyo, Forest Pharmaceuticals, Meiji Seika Pharma, Tonix Pharmaceuticals, Theravance Biopharma.
The fibromyalgia treatment market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Fibromyalgia Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Fibromyalgia Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Fibromyalgia Treatment Market - Supply Chain
4.5. Global Fibromyalgia Treatment Market Forecast
4.5.1. Fibromyalgia Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Fibromyalgia Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Fibromyalgia Treatment Market Absolute $ Opportunity
5. Global Fibromyalgia Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Fibromyalgia Treatment Market Size and Volume Forecast by Type
5.3.1. Antidepressants
5.3.2. Anticonvulsants
5.3.3. Muscle Relaxants
5.3.4. Narcotic Analgesics
5.3.5. Non-narcotic Analgesics
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Fibromyalgia Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Fibromyalgia Treatment Market Size and Volume Forecast by Application
6.3.1. Hospitals Pharmacies
6.3.2. Clinic Pharmacy
6.3.3. Retail Drug Stores
6.3.4. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Fibromyalgia Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Fibromyalgia Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Fibromyalgia Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Fibromyalgia Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Fibromyalgia Treatment Demand Share Forecast, 2019-2026
9. North America Fibromyalgia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Fibromyalgia Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Fibromyalgia Treatment Market Size and Volume Forecast by Application
9.4.1. Hospitals Pharmacies
9.4.2. Clinic Pharmacy
9.4.3. Retail Drug Stores
9.4.4. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Fibromyalgia Treatment Market Size and Volume Forecast by Type
9.7.1. Antidepressants
9.7.2. Anticonvulsants
9.7.3. Muscle Relaxants
9.7.4. Narcotic Analgesics
9.7.5. Non-narcotic Analgesics
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Fibromyalgia Treatment Demand Share Forecast, 2019-2026
10. Latin America Fibromyalgia Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Fibromyalgia Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Fibromyalgia Treatment Market Size and Volume Forecast by Application
10.4.1. Hospitals Pharmacies
10.4.2. Clinic Pharmacy
10.4.3. Retail Drug Stores
10.4.4. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Fibromyalgia Treatment Market Size and Volume Forecast by Type
10.7.1. Antidepressants
10.7.2. Anticonvulsants
10.7.3. Muscle Relaxants
10.7.4. Narcotic Analgesics
10.7.5. Non-narcotic Analgesics
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Fibromyalgia Treatment Demand Share Forecast, 2019-2026
11. Europe Fibromyalgia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Fibromyalgia Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Fibromyalgia Treatment Market Size and Volume Forecast by Application
11.4.1. Hospitals Pharmacies
11.4.2. Clinic Pharmacy
11.4.3. Retail Drug Stores
11.4.4. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Fibromyalgia Treatment Market Size and Volume Forecast by Type
11.7.1. Antidepressants
11.7.2. Anticonvulsants
11.7.3. Muscle Relaxants
11.7.4. Narcotic Analgesics
11.7.5. Non-narcotic Analgesics
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Fibromyalgia Treatment Demand Share, 2019-2026
12. Asia Pacific Fibromyalgia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Fibromyalgia Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Fibromyalgia Treatment Market Size and Volume Forecast by Application
12.4.1. Hospitals Pharmacies
12.4.2. Clinic Pharmacy
12.4.3. Retail Drug Stores
12.4.4. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Fibromyalgia Treatment Market Size and Volume Forecast by Type
12.7.1. Antidepressants
12.7.2. Anticonvulsants
12.7.3. Muscle Relaxants
12.7.4. Narcotic Analgesics
12.7.5. Non-narcotic Analgesics
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Fibromyalgia Treatment Demand Share, 2019-2026
13. Middle East & Africa Fibromyalgia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Fibromyalgia Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Fibromyalgia Treatment Market Size and Volume Forecast by Application
13.4.1. Hospitals Pharmacies
13.4.2. Clinic Pharmacy
13.4.3. Retail Drug Stores
13.4.4. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Fibromyalgia Treatment Market Size and Volume Forecast by Type
13.7.1. Antidepressants
13.7.2. Anticonvulsants
13.7.3. Muscle Relaxants
13.7.4. Narcotic Analgesics
13.7.5. Non-narcotic Analgesics
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Fibromyalgia Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Fibromyalgia Treatment Market: Market Share Analysis
14.2. Fibromyalgia Treatment Distributors and Customers
14.3. Fibromyalgia Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Eli Lilly and Company
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis AG
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Allergan
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Aptinyx
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Prismic Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Innovative Med Concepts
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Intec Pharma Ltd.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Astellas Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Savella
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Sun Pharmaceutical Industries
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Mylan NV
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Teva Pharmaceutical Industries
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Daiichi Sankyo
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Forest Pharmaceuticals
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Meiji Seika Pharma
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Tonix Pharmaceuticals
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Theravance Biopharma
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
